



# International Journal of Medical Research & Health Sciences

www.ijmrhs.com

Volume 3 Issue 2 (April - Jun)

Codon: IJMRHS

Copyright @2014

ISSN: 2319-5886

Received: 26<sup>th</sup> Dec 2013Revised: 24<sup>th</sup> Jan 2014Accepted: 30<sup>th</sup> Jan 2014

Review article

## REVIEW OF NRF2-REGULATED GENES INDUCED IN RESPONSE TO ANTIOXIDANTS

\*Ahmed Atia, Azman Abdullah

Department of Pharmacology, Faculty of Medicine, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.

\*Corresponding author email: elbadri83@yahoo.com

### ABSTRACT

Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a transcription factor that plays an important role in the cellular protection against free radical damage and reduce the incidence of radical derived degenerative diseases such as cancer. Nrf2 is referred to as the "master regulator" of the antioxidant response due to the fact that it modulates the expression of several genes including phase-2 and antioxidant enzymes playing a crucial role in detoxification of electrophiles and reactive oxygen species (ROS), including glutathione-S-transferase (GST), gamma-glutamyl cysteine ligase (-GCL), glutathione-S-reductase (GSR), NAD(P)H:quinoneoxidoreductase-1 (NQO1), heme oxygenase-1 (HO-1), etc. Following dissociation from its obligatory partner Kelch like ECH-associated protein 1 (Keap1), Nrf2 translocates to the nucleus and transactivates the antioxidant response element (ARE) in the promoter region of several antioxidant genes. In this review, we discuss the role of the Nrf2 system, with particular focus on Nrf2-controlled target genes.

**Keyword:** Nrf2- keap1- ROS- Cytoprotective genes.

### INTRODUCTION


Oxidative and electrophilic stresses provoke physiological responses that induce the expression of several cytoprotective genes.<sup>1</sup> The transcription factor Nrf2 was identified as the main regulator of the cytoprotective genes encoding phase 2 detoxification and antioxidant enzymes.<sup>2</sup> Nrf2 originates from studies of  $\alpha$ -globin gene expression with the description of locus control region as possessing substantial regulatory activities, and relates to transcription factor activating protein-1 (AP-1).<sup>3</sup> During the last few years, the role of Nrf2 has been increasingly studied to show that Nrf2 activation can protect against various human diseases such as cancer. Using dietary or synthetic compounds to rise Nrf2-mediated cellular defence responses, Nrf2 has been progressively studied in diseases prevention.<sup>4</sup> Numerous Nrf2 activators have been recognized and

their efficacy in cancer prevention has been established both in animal and human experiments.<sup>5,6</sup> Nrf2 functions to promptly alter the sensitivity of cells to oxidative and electrophilic compounds by stimulating the transcriptional activation of various cytoprotective and detoxification genes, including the antioxidants ferritin<sup>7</sup>, glutathione-S-reductase (GSR), gamma-glutamyl cysteine ligase (-GCL)<sup>8</sup>, NAD(P)H:quinoneoxidoreductase-1 (NQO1), and heme oxygenase-1 (HO-1).<sup>9</sup> In homeostatic status, Nrf2 is constantly ubiquitinated through its inhibitory partner Keap1. In response to electrophiles or ROS stress, cytosolic Nrf2 liberates itself from sequestration or negative regulation of Keap1, thereby releasing Nrf2 from proteasomal degradation and translocates into the nucleus. Once in the nucleus, Nrf2 forms a heterodimer complex with various

transcriptional regulatory proteins such as small Maf(sMaf) protein. This protein complex then binds to the ARE, which is located in the upstream promoter regions, leading to the induction of diverse target cytoprotective genes.<sup>10</sup>

### THE NRF2:INRF2 (OR KEAP1) SYSTEM

The transcription factor Nrf2 is the master of redox homeostasis because it regulates basal and inducible expression of several antioxidants and cytoprotective genes, providing protection against several diseases, such as renal, pulmonary, cardiovascular, neurodegenerative diseases and cancer.<sup>11</sup> Nrf2 is a member of the cap 'n' collar (CNC) family basic region-leucine zipper transcription factor that also includes NF-E2, Nrf1, Nrf3, Bach1, and Bach2.<sup>12</sup> Nrf2 protein has six NRF2-ECH homology domains designated as Neh1-Neh6 respectively.<sup>13</sup> These proteins serve as heterodimeric transcription factors by dimerizing with other bZIP proteins such as the sMaf.<sup>14</sup> As shown in fig. 1, the first conserved domain, Neh1, is located in the half C-terminal of the molecule, constitutes the basic DNA binding domain and the leucine zipper for dimerization with other b-Zip proteins.<sup>15</sup> Neh2 consists of the amino-terminal region of the Nrf2 and serve as a negative regulator of Nrf2.<sup>16</sup> Neh3, in turn, located at the C-terminal end of the protein and required for transcriptional activation of Nrf2.<sup>12</sup> Both Neh4 and Neh5 are considered as transactivation domains, act cooperatively to bind another transcriptional co-activator, the cAMP response element-binding protein (CREB)-binding protein (CBP), in order to organize the start of transcription.<sup>17</sup> Neh6 is a redox-insensitive degron which is essential for negative regulation of Nrf2.<sup>16</sup>



**Fig 1: Nrf2 and Keap1 domains.**

Upper panel: in Nrf2, Neh1 is the basic DNA binding domain and the leucine zipper for dimerization. Neh2

is the Keap1 binding domain. Neh3 is required for transcriptional activation of the protein. Neh4 and Neh5 domains are important for binding to ARE. Neh6 is required for the negative control of Nrf2.

Lower panel: in Keap1, BTB domain serves as a substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. IVR domain is a domain of intervention which is distinguished for its high number of cysteine residues. DGR domain is associated with actin filaments, giving stability to Keap1 (Adapted from Yoichiro et al).<sup>18</sup>

It has been demonstrated that Nrf2 through its Neh2 domain interacts with Keap1 protein, also known as inhibitor of Nrf2 (INrf2), and negatively controls Nrf2 function.<sup>13</sup> Keap1, as shown in fig.1, is composed of five major domains: an N-terminal region (NTR), broad complex, tramtrack, and bric-a-brac domain (BTB), a cysteine-rich intervening region (IVR), the double glycine repeat region (DGR) or Kelch domain, and a C terminal Kelch region (CTR). Keap1 forms a homodimer and each dimer binds one molecule of Nrf2 by its two Kelch domains, with one high affinity binding site (ETGF motif) and one weak affinity binding site (DLG motif). Both motifs are located in Neh2 domain of Nrf2.<sup>19</sup> The ETGF motif has a higher affinity for Keap1 than the DLG motif, and this is the so-called ‘hinge-and-latch’ model.<sup>20</sup> Keap1 contains several reactive cysteine residues that serve as sensors of intracellular redox state, among which C273 and C288, connected to IVR, are critical for the dissociation of Nrf2 from Keap1 under basal conditions and their modulation by inducers may diminish the rate of ubiquitination and degradation of Nrf2. Cysteine residues C151, in the BTB domain, is essential for repression of Nrf2 ubiquitination by electrophiles or oxidants.<sup>21</sup> Oxidative or covalent modification of thiols in some of these cysteine residues cause Nrf2 to be released from Keap1 sequestration with consequent translocation to the nucleus.<sup>22</sup> Once in the nucleus, Nrf2 heterodimerizes with the sMaf protein in the upstream promoter regions of the ARE, leading to the induction of genes encoding antioxidant and phase 2 detoxifying enzyme.<sup>15,23</sup> These cytoprotective enzymes are crucial for cell defence by improving the removal of ROS and, thus, plays a protective role against oxidative stress.<sup>24</sup> Furthermore, Nrf2 is a key transcription factor involved in cytoprotection against

inflammation due to its ability to antagonize the transcription factor nuclear factor- $\kappa$ B (NF- $\kappa$ B), which coordinates the expression of inflammatory genes.<sup>25</sup> Additionally, studies have suggested BTB and CNC homology-1 (Bach1) as another control mechanism for Nrf2 activation. Bach1 is known to bind to the Nrf2 site as a heterodimer with sMaf.<sup>26</sup> Upon induction, Bach1 is substituted by Nrf2, leading to activation and suggesting competition between Bach1 and Nrf2 for the same DNA binding site in various cellular conditions.<sup>27</sup>

### **NRF2 TARGET GENES**

NRF2, as mentioned, is a transcription factor that controls the expression of phase 2 detoxification genes. It heterodimerizes with members of the Maf family of transcription factors and binds to the ARE in the promoter regions of various phase 2 genes. The impacts and functions of some of the main Nrf2-target genes will be discussed below. However, it is not easy to distinguish which particular genes activated by Nrf2 are most significant for its cytoprotective role; nevertheless it is clear that the coordinated induction of those genes has a dramatic effect on cellular homeostasis.

**Glutamate-cysteine ligase (GCL).** GCL, also known as  $\gamma$ -glutamylcysteine synthetase, is an enzyme composed of two subunits: a modifier subunit (GCLM) and a catalytic subunit (GCLC), both of which contain ARE sequences in their promoters.<sup>4,5</sup> GCL catalyzes the first step in glutathione synthesis (GSH), the most significant non-protein thiol in the cell. GSH maintains intracellular redox balance and plays an important role in detoxifying of xenobiotics, electrophiles and protection of the cell from reactive molecules and oxidative insults. GSH can also detoxify chemicals through enzymatic conjugation by glutathione-S-transferases.<sup>28,29</sup> Since GCL is a master determinant of the total capacity of GSH synthesis, regulation of GCL subunits has been subjected to extensive research.<sup>30</sup> Studies have identified that GCL has different levels of regulation, at the kinetic, post translational and transcriptional levels, which ultimately affect either the catalytic or modifier subunits or both.<sup>31</sup> The regulation of GCL at the transcriptional level provides more persistent effect and thus is essential for the maintenance of GSH homeostasis in response to oxidative stress.<sup>32</sup> The

Nrf2/ARE signalling is one of the major regulatory pathways. Both of GCLC and GCLM contain AREs in their promoters.<sup>33</sup> Further, many transcription factors have been reported to bind ARE, such as Nrf2 family members (Nrf1/2/3), sMaf (maf G/K/F), AP-1, and Fos family members (c-Fos, FosB, Fra1, Fra2).<sup>34</sup> Among them, ARE-dependent GCLC gene expression is highly dependent upon Nrf2.<sup>35</sup> In addition, researchers have identified that levels of GCLC and GCLM are decreased in Nrf2 knockout mice, this leads to lack in GSH synthesis which is lethal during embryogenesis.<sup>36</sup>

**Glutathione-S-transferases (GST).** GSTs are multi-gene family of phase II detoxification enzymes that catalyse the conjugation of several endogenous and exogenous electrophilic compounds with GSH.<sup>37</sup> GSTs are largely distributed in nature, being presented in all eukaryotes and in various prokaryotes.<sup>38</sup> In mammals, GSTs are divided into numerous cytosolic, mitochondrial and microsomal GST isoenzymes, also known as MAPEG (membrane associated proteins in eicosanoid and glutathione) proteins, according to their homologies and properties.<sup>39</sup> The cytosolic enzymes are encoded by five related gene families (known as; alpha, mu, pi, sigma, and theta GST), while the membrane-bound enzymes and microsomal GST are encoded by single genes and both have originated separately from the soluble GST.<sup>37</sup> It has been suggested that phase II conjugation enzymes, particularly GSTs, are Nrf2 target genes with an extremely transactivational ARE-like motifs demonstrated on the gene promoter.<sup>24</sup> Studies have revealed that Nrf2 knockout mice exhibited reduced constitutive and inducible expressions of many GST isoforms in livers.<sup>40</sup> Moreover, induction of hepatic and intestinal GST isoforms by Butylated hydroxytoluene (BHA) and ethoxyquin is also reduced in the absence of Nrf2.<sup>41</sup>

**NAD(P)H quinone oxidoreductase 1 (NQO1).** NQO1 is a cytosolic homodimeric flavoprotein that is widely expressed in many tissues, and its expression is regulated by the ARE both in basal and during oxidative stress conditions.<sup>42</sup> NQO1 catalyzes two electron-reduction and detoxification of a wide range of substrates, most prominently quinones and its derivatives, protecting cells from reactive forms of oxygen, oxidative stress, and neoplasia.<sup>43</sup> However, in many cases, the reduction of quinones by NQO1 leads to the formation of cytotoxic hydroquinones which

play a key role in targeting NQO1-rich cancer cells.<sup>44</sup>NQO1 is expressed predominantly in all the tissues, and its level of expression differs among human tissues. NQO1 is expressed at relatively high levels in several tumor tissues including lung, liver, colon, breast and pancreatic tissues, and its expression induced in response to a variety of xenobiotics, antioxidants, oxidants, and heavy metals.<sup>45</sup> Mutations and deletions in the NQO1 gene promoter aided in recognizing the core ARE sequence.<sup>32</sup> ARE is basically needed for expression and coordinated induction of NQO1 and other detoxifying enzyme genes. Nrf2 bind ARE and regulate expression and induction of NQO1 gene. Meanwhile, Nrf2 knockout exhibited reduction in the constitutive expression of NQO1 and impairs its induction.<sup>42</sup>In addition, treatment with BHA, known Nrf2 inducer, increases hepatic and intestinal NQO1 levels in wild-type, but not in Nrf2 knockout mice.<sup>45</sup>All of these data confirm a role for Nrf2 in the expression of NQO1 in various tissues.

**Superoxide dismutases (SODs).** SODs are the first and most significant line of antioxidant enzyme defence systems against several ROS, particularly superoxide anion radicals. SOD is an extremely efficient enzyme, catalyses the dismutation of two superoxide radicals to form hydrogen peroxide and oxygen. Product of this gene is suggested to defend the lungs and other tissues from oxidative stress.<sup>46</sup> In mammals, three distinct isoforms of SOD have been identified; cytoplasmic (SOD1), mitochondrial (SOD2), and extracellular (SOD3).<sup>47</sup> SOD1 is a soluble cytoplasmic protein that binds zinc and copper ions, and works as a homodimer. SOD2, a protein found in mitochondria in a homotetramer form, binds the superoxide byproducts of oxidative phosphorylation and converts them to hydrogen peroxide and diatomic oxygen. SOD3, in turn, is secreted into the extracellular space and forms a glycosylated homotetramer that is linked to the extracellular matrix and cell surfaces via an interaction with heparin sulfate proteoglycan and collagen.<sup>46</sup> Researchers have identified that SOD3 but not SOD2 and SOD1 is induced by antioxidants, and is regulated through Nrf2. Therefore, SOD3 suggested as an important gene in defence against oxidant stress and in the prevention of estrogen-mediated breast cancer.<sup>48</sup>

**Epoxide hydrolases (EHs).**EHs are multifunctional enzymes that are essential for both the activation and inactivation of reactive species. EHs catalyse the hydrolysis of epoxides, which formed by the cytochrome P450-dependent monooxygenase (CYP) superfamily, to a diol (known as dihydrodiols) by the addition of water.<sup>49</sup> Two mammalian enzymes, microsomal (mEH or EPHX1) and soluble epoxide hydrolase (sEH or EPHX2), have been characterized to play diverse roles in xenobiotic metabolism. mEH is expressed in two types. Type-I mEH is typically located in the hepatic endoplasmic reticulum to oppose epoxides of polycyclic aromatics and make them into diols. Type-II mEH is positioned in the hepatocyte plasma membrane, where it controls the absorption of bile acids in the liver in association with a taurocholate binding protein. Meanwhile, Soluble epoxide hydrolase also forms diols from different endogenous and exogenous epoxides, and is expressed in most tissues such as; liver, lung and kidney. sEH regulates many pathways linked to endogenous systems including; fatty acid and leukotriene epoxide metabolism, and is involved in blood pressure regulation and inflammatory responses.<sup>50</sup> There are some evidence indicated that EHs are regulated by the Nrf2 system. The mRNA expression of mEH has shown to be decreased in various tissues of Nrf2 knockout mice. In addition, treatment of Nrf2 knockdown mice with prototypical Nrf2 inducers, oltipraz, have not been found to induce mEH in compare to the wild type. These results highlights a role for Nrf2-mediated control.<sup>51,52</sup>

**Heme oxygenase-1 (HO-1).** HO-1 is the extremely inducible rate-controlling enzyme of heme catabolism.<sup>53</sup> It catalyzes the rate-limiting step in the degradation of heme into biliverdin, carbon monoxide (CO), and free iron.<sup>54</sup>HO-1 has antioxidant, cytoprotective, anti-inflammatory, and immunomodulatory activities. These activities are suggested to be due to its ability to reduce high levels of potentially toxic heme within cells and to alter heme to less reactive iron which can be stored in the nontoxic form of ferritin.<sup>55</sup>HO-1 plays a crucial role in the maintenance of cellular redox homeostasis and subsequently hinders transformation of normal cells to malignant cells by abolishing ROS-mediated carcinogenesis.<sup>56</sup> However, increased levels of HO-1 and Nrf2 have been demonstrated in several types of human malignancies. Studies have reported that Nrf2

regulates the induction of HO-1 in response to diverse forms of cellular stress, including oxidative, hemodynamic, and endoplasmic reticulum stress. Additionally, Nrf2-knockout animals have been found to express HO-1 at low levels, further implicating Nrf2 in the induction of HO-1.<sup>57</sup>

**Multidrug resistance-associated proteins (MRPs):** MRPs are ATP-dependent efflux transporters known to transport a variety of compounds, particularly glutathione, glucuronide, and sulfate conjugates, out of cells. Four MRP transporters (MRP2, 3, 4, and 6) of the eight MRPs are expressed to a significant extent in liver.<sup>58</sup> MRP2 is the only MRP localized to the canalicular membrane and involved in excretion of chemicals into bile. While, MRP3, MRP4 and MRP6 are localized to the basolateral membrane and serve as an efflux pump transporting chemicals from hepatocytes into blood.<sup>59</sup> MRPs play major roles in hepatic removal of metabolites, and modification of MRPs expression in liver can convert drug disposition.<sup>60</sup> MRPs have been demonstrated to be induced by various Nrf2 activators, including BHA, oltipraz, and ethoxyquin.<sup>61</sup> Moreover, other transcription factors, such as NF- $\kappa$ B, have been implicated in MRPs regulation, suggesting that another regulatory mechanism might control MRPs induction.<sup>62</sup>

Beside the mentioned genes that are regulated by Nrf2, there are many other genes regulated by this process that we cannot possibly include them in this review. But, what has shown in this section is the most known genes that regulated by this signalling mechanism, addressing their implication with Nrf2 in cytoprotection against ROS-mediated carcinogenesis.

## SUMMARY

Transcription factor Nrf2 regulates basal and inducible expression of phase II detoxification genes that protect animal cells against toxic effects of electrophiles and ROS. Under normal physiological conditions, Nrf2 is sequestered in the cytoplasm by Keap1, a multi-domain, cysteine-rich protein that is bound to the actin cytoskeleton. Keap1 acts both as a repressor of the Nrf2 transactivation and as a sensor of phase 2 inducers. Electrophiles and oxidative stress loose the interaction between Nrf2 and the Keap1 protein, allowing Nrf2 to translocate to the nucleus, where it forms a heterodimer bound with its

obligatory partner sMaf protein, and eventually activates ARE-dependent gene expression. These genes are essential for detoxification of xenobiotics and endogenous reactive intermediates.

**Conflicts of Interest:** The authors declare that they have no conflict of interests.

## ACKNOWLEDGMENTS

This work is funded by the National University of Malaysia Grant FF-176-2013.

## REFERENCES

1. Nguyen T, Sherratt PJ, Pickett CB. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. *Annu. Rev Pharmacol. Toxicol.* 2003;43:233–60
2. Itoh K, Igarashi K, Hayashi N, Nishizawa M, Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. *Mol Cell Biol.* 1995;15(8):4184-93
3. Tuan D, Solomon W, Li Q, London IM. The beta-like-globin gene domain in human erythroid cells. *Proc Natl Acad Sci USA.* 1985;82(19):6384–88
4. Rushworth S.A, Osborne R.M, Charalambos C.A, O'Connell M.A. Role of protein kinase c delta in curcumin-induced antioxidant response element-mediated gene expression in human monocytes. *Biochem Biophys Res Commun.* 2006;341(4):1007-16
5. Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH et al. Preclinical evaluation of targeting the nrf2 pathway by triterpenoids (cddo-im and cddo-me) for protection from lps-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. *Antioxid. Redox Sign.* 2007;9(11):1963-70
6. Riedl MA, Saxon A, Diaz-Sanchez D. Oral sulforaphane increases phase ii antioxidant enzymes in the human upper airway. *Clin Immunol.* 2009;130(3):244-51
7. Pietsch EC, Chan JY, Torti FM, Torti SV. Nrf2 mediates the induction of ferritin h in response to xenobiotics and cancer

- chemopreventivedithiolethiones. *J Biol Chem.* 2003;278(4):2361-9
8. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y. et al. An nrf2 small maf heterodimer mediates the induction of phase ii detoxifying enzyme genes through antioxidant response elements. *BiochemBiophys Res Commun.* 1997;236(2):313-22
  9. Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharide-induced expression of nad(p)h: Quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. *J Immunol.* 2008;181(10):6730-7
  10. Jain AK, Bloom DA, Jaiswal AK. Nuclear import and export signals in control of Nrf2. *J Biol Chem.* 2005;280(32):29158-68
  11. Cardozo LF, Pedruzzi LM, Stenvinkel P, Stockler-Pinto MB, Daleprane JB, Leite M Jr, Mafra D. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. *Biochimie.* 2013;95(8):1525-33.
  12. Sykiotis GP, Bohmann D. Stress-Activated Cap'n'collar Transcription Factors in Aging and Human Disease. *Sci Signal.* 2010;3(112):re3
  13. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev.* 1999;13(1):76-86
  14. Igarashi K, Kataoka K, Itoh K, Hayashi N, Nishizawa M, Yamamoto M. Regulation of transcription by dimerization of erythroid factor NF E2 p45 with small Maf proteins. *Nature.* 1994;367(6463):568-72
  15. Baird L, Dinkova-Kostova AT. The cytoprotective role of the Keap1-Nrf2 pathway. *Arch Toxicol.* 2011;85(4):241-72
  16. McMahan M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. *J Biol Chem.* 2004;279(30):31556-67
  17. Katoh Y, Itoh K, Yoshida E, Miyagishi M, Fukamizu A, Yamamoto M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. *Genes Cells.* 2001;6(10):857-68
  18. Mitsuishi Y, Motohashi H, Yamamoto M. The Keap1 Nrf2 system in cancers: stress response and anabolic metabolism. *Front Oncol.* 2012;2:200
  19. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, Yamamoto M. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. *Mol Cell Biol.* 2007;27(21):7511-21
  20. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. *MolCell Biol.* 2006;26(8):2887-900
  21. Hu R, Saw CL, Yu R, Kong AN. Regulation of NF-E2-Related Factor 2 Signaling for Cancer Chemoprevention: Antioxidant Coupled with Antiinflammatory. *Antioxid Redox Signal.* 2010;13(11):1679-98
  22. Kim HJ, Vaziri ND. Contribution of impaired Nrf2eKeap1 pathway to oxidative stress and inflammation in chronic renal failure. *Am J Physiol Renal Physiol.* 2010;298(3):F662-71
  23. Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P. Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. *Free Radic Res.* 2010;44(11):1267-88
  24. Rushmore TH, Morton MR, Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. *J Biol Chem.* 1991;266(18):11632-9
  25. Jin W, Wang H, Yan W, Xu L, Wang X, Zhao X et al. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. *Mediators Inflamm.* 2008;2008:725174
  26. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Role of bach1 and nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. *FASEB J.* 2006;20(14):2651-3

27. Kaspar JW, Jaiswal AK. Antioxidant-induced phosphorylation of tyrosine 486 leads to rapid nuclear export of bcl-1 that allows nrf2 to bind to the antioxidant response element and activate defensive gene expression. *J Biol Chem.* 2010;285(1):153-62
28. Koike Y, Hisada T, Utsugi M, Ishizuka T, Shimizu Y, Ono A et al. Glutathione redox regulates airway hyperresponsiveness and airway inflammation in mice. *Am J Respir Cell Mol Biol.* 2007;37(3):322-9
29. Chi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. *Neuroscience.* 2007;144(3):991-1003
30. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. *FASEB J.* 1999;13(10):1169-83
31. Shenvi SV, Smith EJ, Hagen TM. Transcriptional regulation of rat  $\gamma$ -glutamate cysteine ligase catalytic subunit gene is mediated through a distal antioxidant response element. *Pharmacol Res.* 2009;60(4):229-36
32. Nioi P, McMahon M, Itoh K, Yamamoto M, Hayes JD. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinoneoxidoreductase 1 gene: reassessment of the ARE consensus sequence. *Biochem J.* 2003;374(Pt 2):337-48
33. Erickson AM, Nevarea Z, Gipp JJ, Mulcahy RT. Identification of a variant antioxidant response element in the promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the ARE consensus sequence. *J Biol Chem.* 2002;277(34):30730-7
34. Jaiswal AK. Nrf2 signaling in coordinated activation of antioxidant gene expression. *Free RadicBiol Med.* 2004;36(10):1199-207
35. Wild AC, Moinova HR, Mulcahy RT. Regulation of gamma glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. *J Biol Chem.* 1999;274:33627-33636
36. Chan JY, Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic leucine zipper protein. *BiochimBiophysActa.* 2000;1517(1):19-26
37. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Crit Rev BiochemMol Biol.* 1995;30(6):445-600
38. Suzuki T, Takagi Y, Osanai H, Li L, Takeuchi M, Katoh Y et al. Pi class glutathione S-transferase genes are regulated by Nrf2 through an evolutionarily conserved regulatory element in zebrafish. *Biochem J.* 2005;388(Pt 1):65-73
39. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. *Annu Rev PharmacolToxicol.* 2005;45:51-88
40. Chanas SA, Jiang Q, McMahon M, McWalter GK, McLellan LI, Elcombe CR et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. *Biochem J.* 2002;365(Pt 2):405-16
41. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. *J Biol Chem.* 2000;275(21):16023-9
42. Nioi P, Hayes JD. Contribution of NAD(P)H:quinoneoxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. *Mutat Res.* 2004;555(1-2):149-71
43. Jaiswal AK. Regulation of genes encoding NAD(P)H:quinoneoxidoreductases. *Free RadicBiol Med.* 2000;29(3-4):254-62
44. Siegel D, Yan C, Ross D. NAD(P)H:quinoneoxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. *BiochemPharmacol.* 2012;83(8):1033-40
45. Ishii T, Itoh K, Yamamoto M. Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant responsive elements. *Methods Enzymol.* 2002;348:182-90
46. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. *Free RadicBiol Med.* 2002;33(3):337-49

47. Marklund SL. Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. *Biochem J.* 1984;222(3):649-55
48. Singh B, Bhat HK. Superoxide dismutase 3 is induced by antioxidants, inhibits oxidative DNA damage, and is associated with inhibition of estrogen-induced breast cancer. *Carcinogenesis.* 2012;33(12):2601-10
49. Decker M, Arand M, Cronin A. Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. *Arch Toxicol.* 2009;83(4):297-318
50. Michael D. Coleman. *Human Drug Metabolism: an Introduction.* John Wiley & Sons, second edition. 2010;6:149-150
51. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. *ProcNatlAcadSci U S A.* 2001;98(6):3410-5
52. Hu X, Roberts JR, Apopa PL, Kan YW, Ma Q. Accelerated ovarian failure induced by 4-vinyl cyclohexene diepoxide in Nrf2 null mice. *Mol Cell Biol.* 2006;26(3):940-54
53. Elbirt KK, Bonkovsky HL. Hemeoxygenase: recent advances in understanding its regulation and role. *ProcAssoc Am Physicians.* 1999;111(5):438-47
54. Ryter SW, Choi AM. Hemeoxygenase-1: redox regulation of a stress protein in lung and cell culture models. *Antioxid Redox Signal.* 2005;7(1-2):80-91
55. Shan Y, Lambrecht RW, Donohue SE, Bonkovsky HL. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. *FASEB J.* 2006;20(14):2651-3
56. Prawan A, Kundu JK, Surh YJ. Molecular basis of hemeoxygenase-1 induction: implications for chemoprevention and chemoprotection. *Antioxid Redox Signal.* 2005;7(11-12):1688-703
57. Liu XM, Peyton KJ, Ensenat D, Wang H, Hannink M, Alam J, Durante W. Nitric oxide stimulates heme oxygenase-1 gene transcription via the Nrf2/ARE complex to promote vascular smooth muscle cell survival. *Cardiovasc Res.* 2007;75(2):381-9
58. Maher JM, Aleksunes LM, Dieter MZ, Tanaka Y, Peters JM, Manautou JE, Klaassen CD. Nrf2- and ppar alpha-mediated regulation of hepatic mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid. *Toxicol Sci.* 2008;106(2):319-28
59. Madon J, Hagenbuch B, Landmann L, Meier PJ, Stieger B. Transport function and hepatocellular localization of mrp6 in rat liver. *MolPharmacol.* 2000;57(3):634-41
60. Slitt AL, Cherrington NJ, Maher JM, Klaassen CD. Induction of multidrug resistance protein 3 in rat liver is associated with altered vectorial excretion of acetaminophen metabolites. *Drug MetabDispos.* 2003;31(9):1176-86
61. Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. *Drug DrugMetabDispos.* 2005;33(7):956-62
62. Ronaldson PT, Ashraf T, Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: Involvement of nuclear factor-kappab and c-jun n-terminal kinase signaling pathways. *MolPharmacol.* 2010;77(4):644-59